Opparounds

Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder

Deng EK, Huang C, Yan VKC, et al. · American Journal of Psychiatry · September 2026

This self-controlled case series drew on 20 years of Hong Kong electronic health records for 17,841 patients with bipolar disorder, comparing the same patients' outcomes during periods on long-acting injectable antipsychotics (LAIAs) versus periods on oral antipsychotics. LAIA periods had significantly fewer psychiatric hospitalizations and manic-episode admissions — a 49% relative reduction — plus fewer ED visits, with no increase in cardiovascular or other medical admissions. Extrapyramidal symptom risk was transiently higher early in LAIA treatment. Because each patient serves as their own control, the design handles confounding-by-indication better than a typical observational comparison, though it isn't a randomized trial.

Read the paper →  doi:10.1176/appi.ajp.20250793

Takotsubo Syndrome Diagnosis: The Biomarker-Based BioTAK Score

Wenzl FA, Schweiger V, Smolle MA, et al. · European Heart Journal · August 2026

Across two large registries totaling 3,615 patients presenting with suspected acute coronary syndrome, the authors used machine-learning feature selection to build a 5-biomarker BioTAK score — reflecting myocardial stress, vasoconstriction, plaque instability, lipids, and sex — that distinguishes Takotsubo syndrome from true ACS before invasive angiography. Derived in 1,823 patients and externally validated in 1,792 more, the score achieved excellent discrimination (AUC 0.93 in validation) and correctly triaged roughly 90% of patients without an invasive procedure. The authors note current Takotsubo diagnosis leans heavily on psychiatric and neurological history-taking around acute stress.

Read the paper →  doi:10.1093/eurheartj/ehag597

IV Haloperidol's Cardiac Risk Lives in the Cumulative Dose, Not Just the Route

The FDA's 2007 warning followed dozens of case reports of QT prolongation and torsades with IV haloperidol, several fatal — but the mechanism isn't unique to the IV route, it's amplified by it. Bypassing first-pass metabolism means an IV bolus produces a higher, faster peak unbound drug level than the same total dose given orally, and hERG channel blockade is dose-dependent on that peak, not the daily total. Practical thresholds worth knowing: a cumulative IV dose under 2 mg can typically be given without continuous ECG monitoring in a low-risk patient; monitoring is recommended above 5 mg, and telemetry is reserved for cumulative doses at or above 100 mg, or a corrected QTc past 500 ms. The clinical error isn't reaching for IV haloperidol — it's treating repeated small IV doses as if they don't accumulate toward those thresholds the way a running tab does.

The Total Situation Is the Interpretation, Not Just What's Said

Betty Joseph's concept of the total situation holds that transference isn't confined to what a patient says about the therapist — it lives in how the whole session is used: the timing of a disclosure, what happens in a silence, which material gets buried in the final minute. A patient can talk fluently and accurately about the therapist in the third person while enacting the real anxiety through the session's form rather than its content. The technical shift this demands is tracking sequence and pacing alongside explicit content — asking not only what the patient is saying about the relationship, but what they are doing with it, right now, in how this hour is being run. Interpreting content while missing the total situation leaves the most alive material in the room untouched.